Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progesterone vs Observation for Uterine AVM
NCT05491343Phase 4Unknown
- Sponsor
- Emek Medical Center
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of medroxyprogesterone acetate in Uterine arteriovenous malformation (2 arms), sponsored by Emek Medical Center. Primary endpoint: Arteriovenous Malformation regression at 3 weeks. Status: unknown.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Uterine arteriovenous malformation
Beyond the preview
Go deeper on NCT05491343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491343.